Eli Lilly announced on Monday that its daily obesity pill, Foundayo, demonstrated significant efficacy in reducing the severity of obstructive sleep apnea (OSA) in a late-stage clinical trial. The study focused on patients with obesity, showing that the medication effectively mitigates the breathing interruptions associated with the condition. These positive results reinforce the expanding therapeutic profile of GLP-1 treatments, positioning Foundayo as a key contender in the market for managing obesity-related comorbidities alongside weight loss.

The company plans to file for US Food and Drug Administration approval for Foundayo by the end of the year, specifically for the treatment of moderate-to-severe OSA in adults who are overweight or have obesity. OSA is a prevalent condition affecting nearly one billion adults globally, with approximately 80 million individuals in the US aged 20 and older. However, the majority remain undiagnosed due to limited awareness and accessible treatment options. The drug was initially launched in the US in April, primarily recognized for its weight management benefits, but this trial marks a pivotal expansion into respiratory health.

Currently, patients with OSA have limited therapeutic choices outside of Eli Lilly’s blockbuster weight loss injection, Zepbound, which became the first medication to receive US approval for OSA in December 2024. Many patients rely on positive airway pressure (PAP) machines, which are often described as cumbersome and have variable adherence rates. By offering a daily oral alternative that addresses both obesity and sleep apnea, Eli Lilly aims to provide a more convenient and comprehensive treatment solution, potentially impacting the management strategies for millions of patients worldwide suffering from these interconnected conditions.